TrialThe Journal of infectious diseases2025

Safety, Tolerability, and Pharmacokinetics of Once-Monthly Oral Islatravir: A Phase 2a Study in Participants at Low Risk for Acquiring Human Immunodeficiency Virus Type 1.

Sharon L Hillier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.